4960 Peachtree Industrial Boulevard
Suite 240
Norcross, GA 30071
United States
(678) 620-3186
https://galectintherapeutics.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 28
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Joel Lewis | President, CEO & Director | 907.72k | N/A | 1970 |
Mr. Jack W. Callicutt CPA | CFO, Treasurer & Corporate Secretary | 521.47k | N/A | 1967 |
Dr. Pol F. Boudes M.D., Ph.D. | Chief Medical Officer | 730.33k | N/A | 1957 |
Robert Tritt | General Counsel | N/A | N/A | N/A |
Mr. Jeff Katstra | Head of CMC & Pharmaceutical Development | N/A | N/A | N/A |
Ms. Beth Knowles | Executive Assistant & Officer Manager | N/A | N/A | N/A |
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Galectin Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.